论文部分内容阅读
目的探讨食管癌中细胞外基质金属蛋白酶诱导因子(EMMPRIN/CD147)在食管癌血管生成通路中的作用。方法随机抽取41例食管癌患者,其中淋巴结转移17例,应用免疫组化方法检测食管癌病理标本中CD147、血管内皮生长因子(VEGF)、血管内皮细胞生长因子受体2(VEGFR2)的表达及微血管密度(MVD)的计数。结果 41例食管癌肿瘤组织中CD147、VEGF、VEGFR2阳性率分别为83%、54%及71%,明显高于正常组织。CD147、VEGFR2、MVD在淋巴结转移阳性与阴性患者之间存在显著差异(Z=-2.857,P=0.004;Z=-2.018,P=0.044;Z=-4.239,P﹤0.001)。食管造影下食管病变的长度与VEGF、CD147及MVD显著相关(r=0.486,P=0.01;r=0.588,P﹤0.001;r=0.604,P﹤0.001)。CD147与VEGF、VEGFR2、MVD之间均存在显著相关(r=0.976,P﹤0.001;r=0.588,P=0.01;r=0.604,P﹤0.001)。结论 CD147与VEGF、VEGFR2、MVD之间均存在显著相关,与食管病变长度密切相关,提示CD147在食管癌血管生成通路中有重要作用,且可能是通过调控VEGF通路实现的,但尚需进一步研究。
Objective To investigate the role of extracellular matrix metalloproteinase inducer (EMMPRIN / CD147) in esophageal cancer angiogenesis pathway. Methods Totally 41 cases of esophageal cancer were selected from whom 17 cases had lymph node metastasis. The expression of CD147, vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor 2 (VEGFR2) in pathological specimens of esophageal carcinoma were detected by immunohistochemistry Microvascular density (MVD) counts. Results The positive rates of CD147, VEGF and VEGFR2 in 41 cases of esophageal carcinoma were 83%, 54% and 71%, respectively, which were significantly higher than those in normal tissues. There was a significant difference between CD147, VEGFR2 and MVD in patients with positive and negative lymph node metastasis (Z = -2.857, P = 0.004; Z = -2.018, P = 0.044; Z = -4.239, P <0.001). The length of esophageal lesions under esophagectomy was significantly associated with VEGF, CD147 and MVD (r = 0.486, P = 0.01; r = 0.588, P <0.001; r = 0.604, P <0.001). There was a significant correlation between CD147 and VEGF, VEGFR2 and MVD (r = 0.976, P <0.001; r = 0.588, P = 0.01; r = 0.604, P <0.001). Conclusions There is a significant correlation between CD147 and VEGF, VEGFR2 and MVD, which is closely related to the length of esophageal lesions, suggesting that CD147 may play an important role in the angiogenic pathway of esophageal cancer and may be through the regulation of VEGF pathway. However, further study is needed .